open access
Vol 57, No 1 (2023)
Invited Editorial
Submitted: 2023-02-17
Accepted: 2023-02-17
Published online: 2023-02-28
Get Citation
SARS-CoV-2 and the nervous system
1
Affiliations- Department of Neurology, Medical University of Bialystok, Bialystok, Poland
open access
Vol 57, No 1 (2023)
INVITED EDITORIALS — LEADING TOPIC
Submitted: 2023-02-17
Accepted: 2023-02-17
Published online: 2023-02-28
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
SARS-CoV-2 and the nervous system
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Invited Editorial
Pages
3-7
Published online
2023-02-28
Page views
2610
Article views/downloads
399
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2023;57(1):3-7.
Authors
Alina Kułakowska
References (50)- Johns Hopkins University, Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (17.02.2023).
- Czarnowska A, Zajkowska J, Kułakowska A. Impact of SARS-CoV-2 on the nervous system. Neurol Neurochir Pol. 2023; 57(1).
- Stamatovic SM, Johnson AM, Keep RF, et al. Junctional proteins of the blood-brain barrier: New insights into function and dysfunction. Tissue Barriers. 2016; 4(1): e1154641.
- Jasiak-Zatońska M, Michalak S, Osztynowicz K, et al. Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients. Neurol Neurochir Pol. 2022; 56(4): 308–317.
- Jasiak-Zatońska M, Pietrzak A, Wyciszkiewicz A, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022; 56(3): 246–255.
- Suprewicz Ł, Fiedoruk K, Czarnowska A, et al. Blood-brain barrier function in response to SARS-CoV-2 and its spike protein. Neurol Neurochir Pol. 2023; 57(1).
- Chou SHY, Beghi E, Helbok R, et al. GCS-NeuroCOVID Consortium and ENERGY Consortium. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021; 4(5): e2112131.
- Wnuk M, Sawczyńska K, Kęsek T, et al. Neurological symptoms in hospitalised patients with COVID-19 and their association with in-hospital mortality. Neurol Neurochir Pol. 2021; 55(3): 314–321.
- Zielińska-Turek J, Jasińska A, Kołakowska J, et al. Clinical features of neurological patients with coronavirus 2019: an observational study of one centre. Neurol Neurochir Pol. 2021; 55(2): 195–201.
- Franchini M, Marano G, Cruciani M, et al. COVID-19-associated coagulopathy. Diagnosis. 2020; 7(4): 357–363.
- Sawczyńska K, Wrona P, Kęsek T, et al. Mechanical thrombectomy in COVID-19-associated ischaemic stroke: patient characteristics and outcomes in a single-centre study. Neurol Neurochir Pol. 2022; 56(2): 163–170.
- Miękisiak G, Fercho J, Pettersson SD, et al. Impact of COVID-19 on incidence and treatment of intracranial aneurysms in Poland: a national study. Neurol Neurochir Pol. 2022; 56(1): 96–100.
- Sawczyńska K, Wnuk M, Jagiełła J, et al. 4C Mortality Score correlates with in-hospital functional outcome after COVID-19-associated ischaemic stroke. Neurol Neurochir Pol. 2021; 55(3): 295–299.
- Dębiec A, Bilik M, Piasecki P, et al. Effect of COVID-19 pandemic on stroke admissions and quality of stroke interventional treatment in Masovian Voivodeship. Neurol Neurochir Pol. 2021; 55(2): 223–226.
- Słowik A, Nowak R, Popiela T. Significant fall in stroke admissions in the Malopolska Voivodeship of Poland during the COVID-19 pandemic. Neurol Neurochir Pol. 2020; 54(5): 471–472.
- Lasek-Bal A, Członkowska A, Qureshi MM, et al. International study: Global impact of COVID-19 on stroke care - the Polish contribution. Neurol Neurochir Pol. 2023 [Epub ahead of print].
- Straburzyński M, Kuca-Warnawin E, Waliszewska-Prosół M. COVID-19-related headache and innate immune response - a narrative review. Neurol Neurochir Pol. 2022 [Epub ahead of print].
- Sowa P, Dadok A, Adamczyk-Sowa M. SARS-CoV-2 neurotropism and other possible causes of olfactory disorders in COVID-19. Neurol Neurochir Pol. 2023; 57(1).
- Zazhytska M, Kodra A, Hoagland DA, et al. Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia. Cell. 2022; 185(6): 1052–1064.e12.
- Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022; 604(7907): 697–707.
- Dulski J, Sławek J. Incidence and characteristics of post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. Neurol Neurochir Pol. 2023; 57(1).
- Przytuła F, Sławek J. Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update. Neurol Neurochir Pol. 2023; 57(1).
- Przytuła F, Błądek S, Sławek J. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. Neurol Neurochir Pol. 2021; 55(3): 310–313.
- Carfì A, Bernabei R, Landi F, et al. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324(6): 603–605.
- Tenforde MW, Kim SS, Lindsell CJ, et al. IVY Network Investigators, CDC COVID-19 Response Team, IVY Network Investigators. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(30): 993–998.
- Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27(4): 601–615.
- Chopra V, Flanders SA, O'Malley M, et al. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021; 174(4): 576–578.
- Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5): 337–343.
- Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021; 27(2): 258–263.
- Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021; 76(4): 399–401.
- Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82(3): 378–383.
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270): 220–232.
- Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998; 158(5 Pt 1): 1384–1387.
- González-Herazo MA, Silva-Muñoz DC, Guevara-Martínez PA, et al. Post-COVID 19 Neurological Syndrome: a fresh challenge in neurological management. Neurol Neurochir Pol. 2021; 55(4): 413–414.
- Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021; 8(5): 416–427.
- Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021; 93(2): 1013–1022.
- Czarnowska A, Kapica-Topczewska K, Zajkowska O, et al. Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland. J Clin Med. 2021; 10(22).
- Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022; 9(10): 815–827.
- Chatys-Bogacka Ż, Mazurkiewicz I, Słowik J, et al. Sex-related patient-reported brain fog symptoms in non-hospitalised COVID-19 patients. Neurol Neurochir Pol. 2023; 57(1).
- Mazurkiewicz I, Chatys-Bogacka Ż, Słowik J, et al. The course of fatigue among patients previously hospitalized due to COVID-19. Neurol Neurochir Pol. 2023; 57(1).
- Czarnowska A, Brola W, Zajkowska O, et al. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience. Neurol Neurochir Pol. 2021; 55(2): 212–222.
- Rzepiński Ł, Zawadka-Kunikowska M. COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study. Neurol Neurochir Pol. 2022; 56(1): 61–67.
- Rzepiński Ł, Wawrzyniak S, Maciejek Z. Immunocompromised myasthenia gravis patient not infected with SARS-CoV-2 after close exposure - what is the risk of COVID-19? Neurol Neurochir Pol. 2020; 54(5): 481–482.
- Dyczkowska K, Kalinowska-Łyszczarz A. Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians. Neurol Neurochir Pol. 2023 [Epub ahead of print].
- Morawiec N, Adamczyk B, Adamczyk-Sowa M. COVID-19 and autoimmune diseses of the nervous system — an updte. Neurol Neurochir Pol. 2023; 57(1).
- Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol. 2021; 55(1): 8–11.
- Czarnowska A, Tarasiuk J, Zajkowska O, et al. Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. Vaccines (Basel). 2022; 10(5).
- Czarnowska A, Tarasiuk J, Zajkowska O, et al. Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland. Front Neurol. 2022; 13: 913283.
- Kulikowska J, Czarnowska A, Gudowska-Sawczuk M, et al. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies. Neurol Neurochir Pol. 2022 [Epub ahead of print].
- Brola W. Immune response to COVID-19 vaccines in patients with multiple sclerosis treated with disease-modifying therapies. Neurol Neurochir Pol. 2022 [Epub ahead of print].
